fbpx

DCB Newsletter #3/24: The DCB Open Innovation Challenge is back!

DCB Newsletter #3/24: The DCB Open Innovation Challenge is back!

Dear community,

it’s that time of the year again…the DCB Open Innovation Challenge is back – and this time, it’s stronger than ever! Do you have an innovative idea to improve diabetes management with diabetes technology? Then continue reading and learn more about the challenge, important deadlines and what’s in it for you! 🚀

Can your idea change diabetes management forever?

Do you have an innovative idea to facilitate change diabetes management forever? Want to see how your idea becomes reality? Do you have valuable insights to help co-create the diabetes technology of tomorrow? Do you have feedback to share with others in the community?

We are looking for innovators, co-creators, scientists and diabetes supporters from around the world to join our open idea call and be part of an innovative community at the forefront of diabetes technology.

Now you might be thinking, “That’s great, but what does it have to do with diabetes?”. Most people would perhaps consider diabetes as the opposite of a rare disease when about 537 million people worldwide live with the disease, making it a prevalence of 1 in 10 [3].

However, most outlets usually only cover the most common type 1, type 2 and gestational diabetes. In reality, there are many other types which are considered rare types, and some of them are results of rare diseases. In this newsletter, we want to draw your attention to some of them, to honor all people living with diabetes – no matter how rare the type!

What’s in it for you?

  • the chance to win USD 100,000 in funding and in-kind support
  • a chance to participate in our one-week bootcamp with mentoring & co-learning, and a pitch training worth CHF 5,000
  • access to a network of experts from the Diabetes Center Berne, @Diabetes Technology Society, and others
  • a kick-start to your business with first class coaching and training
  • a safe harbour where your idea remains entirely yours

Everything at a glance – this is the timeline of our 2024 Innovation Challenge!

Ema Grabenweger, Innovation Manager at DCB and responsible for the challenge, says: “Our challenge is an excellent opportunity for anyone who would like to get expert guidance on their idea in diabetes technology. Through a carefully designed process we provide a compass for innovators on all levels to efficiently & successfully navigate the complex landscape of developing a medical product or solution to improve the lives of PwD. We do that by offering an open innovation platform for exchange with the community, connection to international experts and mentors who can support to shape the ideas, exposure to venture capitalists and experienced start ups, world-class bootcamp training in the beautiful Swiss Alps tailored to innovator needs. Additionally, the top 6 finalists get to present in front of >300 people in Switzerland and have the opportunity to win an award of USD 100,000 in cash and in-kind service. All of that while having fun! Join our community and make your idea dreams come true!”

Ready to become part of diabetes innovation?

All you have to do is register on our Innovation Platform at https://innovation.dcberne.com/ and submit your idea! All former participants (excluding the finalists) of the past years can also apply again, given their idea has been developed further since the last participation.

Idea submission is still open until April 30 – get the word out and apply! You can find more information on https://www.dcberne.com/en/innovation-challenge/

Whether you are a start-up, a healthcare professional, researcher or an individual, if you have an idea or insight on how to improve the lives of people with diabetes, we want to hear from you! Thank you so much for reading and see you soon for the next edition of the DCB Newsletter!

This post was previously published in Linkedin. Click here to see the original publication.

Melden Sie sich für unseren Newsletter an, um aktuelle Nachrichten zu erhalten.

* Pflichtfelder
DSGVO *

DCB Research AG

Freiburgstrasse 3
3010 Bern
Switzerland

DCB Newsletter #2/24: DID YOU KNOW… you can help crowdfund innovative diabetes education for South Africans?

DCB Newsletter #2/24: DID YOU KNOW… you can help crowdfund innovative diabetes education for South Africans?

Dear Community, we are happy to present you with the next episode of our series “DID YOU KNOW” – this time, with a specific connection to our crowdfunding initiative. In this edition, we want to tell you about the impactful work of Sweet Life Diabetes Community and how you can help them make an even bigger impact. Enjoy the read!

Back in November, during our long-awaited DCB Start-Up Night, we successfully launched our very first crowdfunding initiative, supporting the People’s Diabetes Foundation Belize.

At the very same time, Bridget McNulty was on that same stage pitching for her initiative Africa Diabetes Chat as a finalist in our DCB Open Innovation Challenge. She scored second place in the category Digital Diabetes and we’ve maintained a valuable exchange ever since. Now, it’s time to combine all of those efforts and reach out to the whole community – to get the innovative Africa Diabetes Chat WhatsApp chatbot from the big stage into the hands of the people who need it most.

Join us in crowdfunding CHF 5,000 for the project and help us give South Africans with diabetes the tools they need to survive: Donate now!

Meet Bridget from the Sweet Life Diabetes Communityin South Africa

Sweet Life is South Africa’s largest online diabetes community. They’re a non-profit and a public benefit organisation, and the primary focus is on diabetes education that people can understand, and relate to. Diabetes is the number one killer of women in South Africa, the number two killer of men. There is no national diabetes education programme, which means people don’t understand their condition – they are dying unnecessarily. Sweet Life is South Africa’s leading voice in diabetes, and they have an innovative solution for the problem: a WhatsApp diabetes education chatbot! Listen to Bridget tell their story and learn how Africa Diabetes Chat will help many people living with diabetes in South Africa:

Empower South Africans with diabetes: the Sweet Life chatbot

How will your donation help?

 

Your donation helps give South Africans with diabetes the tools they need to stay alive. We all know that “knowledge is power”, but that knowledge has to actually be in the right format, and the right language, at the right health literacy level, to the right person – exactly when they need it. A WhatsApp chatbot has the power to do exactly that and each donation to our crowdfunding campaign empowers more South Africans with diabetes!

 

Where will your donation go?

Sweet Life Diabetes Community has spent the last three years developing foundational diabetes education content that they have been sending to clinics nationwide in leaflet form. The problem with print, however, is that it’s expensive and difficult to distribute. WhatsApp solves this problem by giving them direct access to people on their phones (there is a staggering 96% WhatsApp penetration in South Africa!)

Your donation will fund the full-time project manager, content development (text, images, video), translation and – critically – monitoring and evaluation. They have created focus groups across South Africa to test that this chatbot is truly useful, and understandable. The community is at the heart of everything we do – and that’s one big part of why we at Diabetes Center Berne want to support this impactful initiative.

Donate Now and Help Us Crowdfund Innovative Diabetes Education in South Africa

 

A little donation can make a big impact for people living with diabetes in South Africa – luckily, Swiss Francs translate to a lot of South African Rands! Any donation you can offer helps more South Africans with diabetes get the tools they need to stay alive. Join our crowdfunding for Africa Diabetes Chat by Sweet Life Diabetes Community and help us make a lasting impact: Donate now on wemakeit!

For any further questions about this crowdfunding initiative, please feel free to contact Svea Krutisch at DCB or Bridget McNulty at Sweet Life Diabetes Community.

Thanks so much for reading and we’ll provide you with the next episode of our newsletter soon!

This post was previously published in Linkedin. Click here to see the original publication.

Neuigkeiten

Melden Sie sich für unseren Newsletter an, um aktuelle Nachrichten zu erhalten.

* Pflichtfelder
DSGVO *

DCB Research AG

Freiburgstrasse 3
3010 Bern
Switzerland

DCB Newsletter #1/24: DID YOU KNOW… that there are Rare Types of Diabetes?

DCB Newsletter #1/24: DID YOU KNOW… that there are Rare Types of Diabetes?

Dear Community,

we are happy to present you with the next episode of our series “DID YOU KNOW” in which we publish interesting facts about life with diabetes that you might not know yet. In this edition, on the special occasion of Rare Disease Day, we want to focus on the rare and lesser known types of diabetes. Enjoy the read!

Today is 29 February – the rarest day of the year, only occurring every 4 years during a leap year. As rare as this day – or most of the times even rarer – are many diseases which qualify as “rare diseases”. Between 7,000 and 8,000 rare diseases have been identified worldwide and around 300 million people live with at least one [1, 2]. Rare Disease Day was brought to life by advocacy organisations as an opportunity to raise awareness for rare diseases and to call for a human rights priority at local, national and international level.

Now you might be thinking, “That’s great, but what does it have to do with diabetes?”. Most people would perhaps consider diabetes as the opposite of a rare disease when about 537 million people worldwide live with the disease, making it a prevalence of 1 in 10 [3].

However, most outlets usually only cover the most common type 1, type 2 and gestational diabetes. In reality, there are many other types which are considered rare types, and some of them are results of rare diseases. In this newsletter, we want to draw your attention to some of them, to honor all people living with diabetes – no matter how rare the type!

Secondary Diabetes

Rare forms of diabetes are often classified as “secondary diabetes”, meaning that the manifestation of diabetes is the result of another disease or medication [5]. There are different types, induced by either genetic mutations, different syndromes or medications such as steroids [5].

MODY (Maturity Onset Diabetes of the Young)

MODY is a rare form of monogenic diabetes, caused by a mutation in a single gene. If a parent has it, children have a 50% chance of inheriting it. With only 1-2% of all people with diabetes living with MODY, it is very rare compared to the common types. Because of its rare character, it is estimated that 90% of people are misdiagnosed with either type 1 or type 2 diabetes at first [4]. MODY typically manifests under the age of 25 and treatment does not necessarily require insulin. There are many different subtypes, depending on which gene the mutation occurs in [4].

 

Cystic Fibrosis Diabetes

As the name suggests, this type of diabetes is a result of the genetic condition Cystic Fibrosis. While people living with Cystic Fibrosis can also develop type 1 or type 2 diabetes, Cystic Fibrosis Diabetes is considered a separate type. It is caused by sticky mucus typical in Cystic Fibrosis scarring the pancreas and damaging the parts responsible for insulin production [6].

 

Type 3c Diabetes

Type 3c Diabetes is often also referred to as “pancreatogenic diabetes” – it is caused by damage to the pancreas, or its removal [7]. Reasons for the development can thus be an acute or chronic inflammation of the pancreas, pancreatic cancer or other conditions. Type 3c Diabetes can be managed with medication or insulin injection, depending on the extent of pancreatic damage [7].

 

Alström Syndrome

Alström syndrome is an extremely rare disease, estimated to affect less than 1 in a million [8]. It is a genetically inherited syndrome which affects eyesight, hearing and other parts of the body. As a result of Alström Syndrome, people often develop an insulin resistance and a type 2 diabetes [9].

 

Wolfram Syndrome

Wolfram Syndrome is a very rare genetic disorder estimated to affect 1 in 160,000–770,000 people [11]. It is often also referred to as “DIDMOAD syndrome” – an acronym for its four most common features Diabetes Insipidus, Diabetes Mellitus, Optic Atrophy and Deafness [10]. The Diabetes Mellitus which comes with this syndrome is different to other types of diabetes and usually manifests during childhood [11]. It is commonly treated with insulin, similar to type 1 diabetes [10].

There are many more subcategories and other genetic disorders that can cause the onset of type 2 or type 1 diabetes, or classify as an entirely different type. To mark Rare Disease Day, we want to hold space for all of these types and the medical diversity within Diabetes Mellitus. Whereas at DCB, we commonly interact with the common types of diabetes, diabetes technologies can benefit all people living with diabetes, regardless of type and pathophysiology. Our aim is to make life easier for all people living with diabetes – including extremely rare forms.

Thanks so much for reading and we’ll provide you with the next episode of this series soon!

[1] Federal Office of Public Health Switzerland: Numerous Rare Diseases and Many People Affected.

[2] Rare Disease Day: What is a Rare Disease?

[3] IDF Diabetes Atlas

[4] Diabetes UK: MODY

[5] Nomiyama T, Yanase T. [Secondary diabetes]. Nihon Rinsho. 2015 Dec;73(12):2008-12. Japanese. PMID: 26666145.

[6] Diabetes UK: Cystic Fibrosis Diabetes

[7] Marshall JD, Maffei P, Collin GB, Naggert JK. Alström syndrome: genetics and clinical overview. Curr Genomics. 2011 May;12(3): 225-35. doi: 10.2174/138920211795677912. PMID: 22043170; PMCID: PMC3137007.

[8] Diabetes UK: Type 3c Diabetes

[9] Alström Syndrome UK: Alström Syndrome

[10] Diabetes UK: Wolfram Syndrome

[11] Urano F. Wolfram Syndrome: Diagnosis, Management, and Treatment. Curr Diab Rep. 2016 Jan;16(1):6. doi: 10.1007/s11892-015-0702-6. PMID: 26742931; PMCID: PMC4705145.

This edition was authored by DCB Digital Communications Specialist Svea Krutisch.

This post was previously published in Linkedin. Click here to see the original publication.

Melden Sie sich für unseren Newsletter an, um aktuelle Nachrichten zu erhalten.

* Pflichtfelder
DSGVO *

DCB Research AG

Freiburgstrasse 3
3010 Bern
Switzerland

Die DCB Open Innovation Challenge ist zurück: Jetzt Idee einreichen!

Die DCB Open Innovation Challenge ist zurück: Jetzt Idee einreichen!

Die DCB Open Innovation Challenge ist zurück: Jetzt Idee einreichen!

Zum vierten Mal lanciert das Diabetes Center Berne die Open Innovation Challenge mit dem Ziel, innovative Projekte im Bereich des Diabetes-Managements auf schweizerischer und internationaler Ebene gezielt zu fördern. Die teilnehmenden Innovator:innen profitieren vom Feedback professioneller Expert:innen, und die sechs besten Projekte erhalten Zugang zu einem Bootcamp. Den Finalist:innen winkt ein Preisgeld von bis zu 100.000 USD sowie weitere Unterstützung durch das DCB. Die DCB Innovation Challenge ist der weltweit grösste Diabetes-Technologiepreis mit internationalem Appeal.

Kann deine Idee das Diabetesmanagement verändern?

Weltweit leben über 537 Millionen Menschen mit Diabetes, was für sie eine stetige Herausforderung im Alltag bedeutet. Technologische Innovationen leisten einen wichtigen Beitrag, um den Umgang mit Diabetes zu erleichtern – sei es die Messung des Blutzuckerspiegels, die Planung der benötigten Insulinmenge per App oder auch die Nutzung automatischer Insulinabgabesysteme. Doch trotz dieser enormen Fortschritte in der Diabetestechnologie besteht immer noch ein grosser, ungedeckter Bedarf an innovativen technischen Lösungen. Diese sollen dazu beitragen, die Herausforderung für die Nutzer:innen im Alltag zu erleichtern und das Leben von Menschen mit Diabetes nachhaltig zu verbessern.

Die DCB Open Innovation Challenge wurde 2021 mit dem Ziel initiiert, diese Lücken in der Diabetestechnologie durch translationale Forschung zu schließen. Ziel der Challenge ist es, einzigartige Lösungen zu finden, die das Leben von Menschen mit Diabetes erleichtern. Egal, ob Forscher:in, Angehörige:r eines Gesundheitsberufs, Gründer:in eines Start-ups oder Mensch mit Diabetes – eure Ideen sind für uns von unschätzbarem Wert. Wir sind auf der Suche nach vielfältigen Perspektiven und innovativen Lösungen, um die Lebensqualität von Menschen mit Diabetes zu verbessern.

 

Was springt für dich dabei heraus?

Nach einer ersten Runde und dem Feedback der Fachjury nehmen die besten 20 an einem Mentoring-Programm teil. Zwei US-Innovator:innen und vier Innovator:innen aus dem Rest der Welt werden zu einem individuell zugeschnittenen Bootcamp in den malerischen Schweizer Alpen eingeladen und werden dann ihre endgültigen Ideen bei der großen DCB Start-Up Night am 3. Oktober 2024 in Bern vorstellen. Außerdem haben alle Finalist:innen die Möglichkeit, ihre Ideen auf dem Diabetes Technology Meeting in den USA vom 15. bis 17. Oktober 2024 zu präsentieren.

Das Siegerprojekt wird von einer internationalen Expertenjury ausgewählt und mit 100.000 USD in Form von Geld- und Sachleistungen belohnt. Damit ist die DCB Open Innovation Challenge der weltweit größte Diabetes-Technologiepreis mit internationalem Appeal. Du erhältst Zugang zu einem globalen Netzwerk von Expert:innen aus der Branche – und die Idee bleibt dabei ganz allein deine.

Verpasse nicht diese einmalige Gelegenheit, deine Idee in die Realität umzusetzen. Reiche deine Idee bis zum 30. April auf unserer Innovationsplattform innovation.dcberne.com ein.

Neuigkeiten

Melden Sie sich für unseren Newsletter an, um aktuelle Nachrichten zu erhalten.

* Pflichtfelder
DSGVO *

DCB Research AG

Freiburgstrasse 3
3010 Bern
Switzerland

Lisa Koch wird Professorin für Artificial Intelligence und Data Science am DCB

Lisa Koch wird Professorin für Artificial Intelligence und Data Science am DCB

Lisa Koch wird Professorin für Artificial Intelligence und Data Science am DCB

Bern, 2. April 2024 Die neu geschaffene Assistenzprofessur mit Tenure Track ist die dritte von insgesamt drei Professuren im Bereich “Diabetestechnologie und künstliche Bauchspeicheldrüse”, die gemeinsam von der Universität Bern, der Inselgruppe und dem Diabetes Center Berne (DCB) geschaffen werden. 

Hintergrund in der Entwicklung von Data Science Produkten für Medizinprodukte

Bevor sie ihre neue Stelle antrat, arbeitete Lisa Koch an Machine Learning für die biomedizinische Datenanalyse. Sie verfügt über einen Hintergrund in der akademischen Forschung sowie in der Entwicklung von datenwissenschaftlichen Produkten für medizinische Geräte, wobei ihr Schwerpunkt auf Technologien liegt, die letztlich der Gesundheit der Menschen auf sichere und vertrauenswürdige Weise zugutekommen können. 

Nach einem Bachelor-Abschluss in Elektrotechnik (BSc) und Biomedizintechnik (MSc) an der ETH Zürich, Schweiz, promovierte Lisa Koch am Imperial College London, UK, im Bereich maschinelles Lernen für die medizinische Bildanalyse.  Nach einem Postdoc-Aufenthalt an der ETH Zürich wechselte sie zum Schweizer Startup Ava, wo sie schliesslich die Leitung des Data-Science-Teams übernahm. In dieser Position lernte sie die Notwendigkeit von nachweislich sicherem Machine Learning im Gesundheitswesen kennen.

Sichere, verlässliche und effektive Tools für Data Science

Im Jahr 2021 kehrte Lisa Koch in die akademische Forschung zurück, um dieses Thema als Gruppenleiterin für Machine Learning in der medizinischen Diagnostik am Hertie-Institut für Artificial Intelligence in der Hirnforschung an der Universität Tübingen, Deutschland, weiter zu verfolgen. In ihrer neuen Rolle als Assistenzprofessorin an der Universität Bern ist es ihr langfristiges Ziel, nachweislich sichere, zuverlässige und effektive Data-Science-Tools für patientenspezifische Behandlungssysteme in der Diabetesversorgung zu entwickeln.

“Mit meiner Forschung möchte ich eine vertrauenswürdige, AI-gestützte Diabetesversorgung bieten, die Patienten und Ärzten einen echten Nutzen bringt. Ich freue mich sehr, dem interdisziplinären Ökosystem des Diabetes Center Berne und der Klinik für Diabetologie, Endokrinologie, Ernährungsmedizin und Stoffwechsel der Universität Bern (UDEM) beizutreten ein ideales Umfeld, um diese Vision voranzutreiben”,

sagt Koch. 

Derek Brandt, CEO des DCB ergänzt: “Neben Lilian Witthauer, Professorin im Bereich Sensortechnologie, und José Garcia Tirado, Professor für technologiegestützte Präzisionsmedizin, haben wir mit Professor Koch einen dritten und wichtigen Schritt für das Thema Artificial Intelligence (AI) und Data Science in der Diabetesversorgung gemacht. Damit können wir unsere internationale Vorreiterrolle auf dem Gebiet der translationalen Diabetes-Technologieforschung weiter stärken. Wir werden auch weiterhin alles tun, um den Alltag von Menschen mit Diabetes zu verbessern. 

Lisa Koch

Downloads

More recent news

Melden Sie sich für unseren Newsletter an, um aktuelle Nachrichten zu erhalten.

* Pflichtfelder
DSGVO *